News & Press Releases

 

Robert Jacks Robert Jacks

Sparrow Pharmaceuticals to Present Two Abstracts at ACR Convergence 2024 and Expand Phase 2 Clinical Trial of Clofutriben with Prednisolone for Polymyalgia Rheumatica to Fifth Cohort

Sparrow Pharmaceuticals will present interim data from the ongoing Phase 2 trial of lead agent clofutriben in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) at the American College of Rheumatology Convergence 2024 conference. Sparrow also announced that the trial has been expanded with a fifth cohort based on encouraging results from the first four cohorts.

Read More
Robert Jacks Robert Jacks

Sparrow Pharmaceuticals Presents Novel Data on Clofutriben (SPI-62) Reducing Glucocorticoid Toxicities with a Low Risk of Adrenal Insufficiency at the 2024 Annual Endocrine Society Conference

Sparrow Pharmaceuticals announced today that, to date, the HSD-1 inhibitor clofutriben (SPI-62) has normalized urine free cortisol (UFC) in >60% of patients with endogenous Cushing’s syndrome (EnCS) without suppressing serum cortisol to levels considered to indicate risk for adrenal insufficiency (AI).

Read More
Robert Jacks Robert Jacks

Sparrow Pharmaceuticals Announces First Patient Rolled-Over to Open-Label Extension of RESCUE, a Phase 2 Clinical Trial of SPI-62 for ACTH-Dependent Cushing’s Syndrome

Sparrow Pharmaceuticals today announced the first patient has elected to enroll in the open-label extension (OLE) phase of the RESCUE trial, a phase 2 clinical trial of SPI-62 for the treatment of ACTH-dependent Cushing’s syndrome. The long-term OLE will be open to patients who complete the initial RESCUE cross-over treatment protocol and then elect to continue to participate in the research.

Read More
Kyle Kostesich Kyle Kostesich

Sparrow Pharmaceuticals Presents Pharmacology Data on SPI-62 at American College of Rheumatology Convergence 2022

Sparrow Pharmaceuticals today presented pharmacology data during an online poster session on SPI-62, a HSD-1 inhibitor, at the American College of Rheumatology (ACR) Convergence 2022 meeting. The presentation titled, “Toward Safer Glucocorticoid Therapy” examined the ability of SPI-62 to mitigate the adverse effects of exogenously administered corticosterone (CORT) in mouse, with results suggesting SPI-62 has the potential to prevent the adverse effects of glucocorticoids.

Read More
Kyle Kostesich Kyle Kostesich

Sparrow Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica

Sparrow Pharmaceuticals today announced that the first patient has been dosed in a phase 2 clinical trial of prednisolone in combination with SPI-62, Sparrow’s potent and selective investigational HSD-1 inhibitor, for the treatment of polymyalgia rheumatica (PMR), a common autoimmune disease that causes widespread muscle pain and stiffness primarily in adults over 50. A fixed-dose combination of prednisolone and SPI-62 will be referred to as SPI-47.

Read More
Kyle Kostesich Kyle Kostesich

Sparrow Pharmaceuticals Presents Clinical Trial Data Analyses on HSD-1 Inhibitor SPI-62 at the Endocrine Society (ENDO) 2022 Annual Meeting

Sparrow Pharmaceuticals today presented new pharmacological data during a poster session and a Rapid Communications session titled, “HPA axis modulation by a potent inhibitor indicates 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) is a main source of cortisol that can bind intracellular receptors” at the 24th European Congress of Endocrinology (ECE 2022).

Read More
Kyle Kostesich Kyle Kostesich

Sparrow Pharmaceuticals Presents New Pharmacological Data on HSD-1 Inhibitor SPI-62 at the 2022 Annual European Congress of Rheumatology

Sparrow Pharmaceuticals today presented new animal model data during an in-person poster session titled, “Toward Safer Glucocorticoid Therapy of Polymyalgia Rheumatica” at the 2022 Annual European Congress of Rheumatology (EULAR 2022). The results of the study suggest that SPI-62 has the potential to mitigate adverse effects of glucocorticoids.

Read More
Kyle Kostesich Kyle Kostesich

Sparrow Pharmaceuticals Presents New Clinical Trial Data Analyses on HSD-1 Inhibitor SPI-62 at the 24th European Congress of Endocrinology

Sparrow Pharmaceuticals today presented new pharmacological data during a poster session and a Rapid Communications session titled, “HPA axis modulation by a potent inhibitor indicates 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) is a main source of cortisol that can bind intracellular receptors” at the 24th European Congress of Endocrinology (ECE 2022).

Read More
Kyle Kostesich Kyle Kostesich

Sparrow Pharmaceuticals Announces FDA Clearance of IND for SPI-62 for the Treatment of Cushing’s Syndrome

Sparrow Pharmaceuticals today announced that the FDA has cleared an IND that enables the company to proceed with initiating a phase 2 clinical trial to study SPI-62 for the treatment of ACTH-dependent Cushing’s syndrome. The company also announced that it has expanded its clinical capabilities by hiring Kim Hunsicker as Head of Clinical Operations and Sarah Hooper as Clinical Project Manager.

Read More